1. Home
  2. GAUZ vs MBRX Comparison

GAUZ vs MBRX Comparison

Compare GAUZ & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gauzy Ltd. Ordinary Shares

GAUZ

Gauzy Ltd. Ordinary Shares

N/A

Current Price

$0.62

Market Cap

15.5M

Sector

Miscellaneous

ML Signal

N/A

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

N/A

Current Price

$2.35

Market Cap

13.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GAUZ
MBRX
Founded
2009
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.5M
13.1M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
GAUZ
MBRX
Price
$0.62
$2.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$11.50
$61.00
AVG Volume (30 Days)
591.4K
258.5K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.59
N/A
Revenue Next Year
$59.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$0.25
52 Week High
$9.60
$7.98

Technical Indicators

Market Signals
Indicator
GAUZ
MBRX
Relative Strength Index (RSI) 44.51 44.49
Support Level $0.48 $2.16
Resistance Level $0.84 $2.64
Average True Range (ATR) 0.10 0.20
MACD -0.01 -0.01
Stochastic Oscillator 13.45 10.46

Price Performance

Historical Comparison
GAUZ
MBRX

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: